TRANSFORMER研究:双相雄激素治疗对比恩杂鲁胺治疗无症状转移性去势抵抗性前列腺癌的随机II期研究
BAT组PSA50应答率28.2% vs 恩杂鲁胺组25.3%,交叉后BAT→恩杂鲁胺的PSA50应答率77.8%。BAT不良事件主要为1-2级,患者报告的生活质量持续偏向BAT。
要点
- BAT与恩杂鲁胺一线PFS相似(均5.7个月),但BAT可增敏后续抗雄激素治疗。
- BAT安全性良好,不良事件以1-2级为主,生活质量优于恩杂鲁胺。
核心结论
- 本随机试验证实BAT在CRPC中具有明确的临床活性和安全性,支持进一步研究其最佳临床整合方式。
- BAT可使CRPC对后续抗雄激素治疗增敏,但BAT与恩杂鲁胺序贯治疗能否改善生存尚需进一步研究确认。
研究设计与样本
- TRANSFORMER研究是一项随机II期研究,比较每月BAT(n=94)与恩杂鲁胺(n=101)在无症状转移性CRPC患者中的疗效。
- 主要终点为临床或影像学无进展生存期(PFS),允许进展后交叉。
- 次要终点包括总生存期(OS)、PSA和客观缓解率、随机至交叉的PFS(PFS2)、安全性和生活质量(QoL)。
主要发现
- BAT组PSA50应答率28.2%,恩杂鲁胺组25.3%。
- 交叉后,转入恩杂鲁胺者PSA50应答率77.8%,转入BAT者23.4%。
- 恩杂鲁胺的PSA-PFS从阿比特龙后3.8个月增至BAT后10.9个月。
临床怎么用
- BAT可作为无症状mCRPC患者的一种治疗选择,尤其考虑后续序贯恩杂鲁胺时可能增敏。
- BAT不良事件以1-2级为主,患者报告的生活质量持续偏向BAT,支持其作为耐受性良好的方案。
局限性
- 本研究为II期随机研究,样本量有限,OS数据尚未成熟,序贯治疗对生存的改善需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of the androgen receptor in response to the low-testosterone microenvironment. Bipolar androgen therapy (BAT), defined as rapid cycling between high and low serum testosterone, disrupts this adaptive regulation in castration-resistant PCa (CRPC). METHODS: The TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) study is a randomized study comparing monthly BAT (n = 94) with enzalutamide (n = 101). The primary end point was clinical or radiographic progression-free survival (PFS); crossover was permitted at progression. Secondary end points included overall survival (OS), prostate-specific antigen (PSA) and objective response rates, PFS from randomization through crossover (PFS2), safety, and quality of life (QoL). RESULTS: The PFS was 5.7 months for both arms (hazard ratio [HR], 1.14; 95% CI, 0.83 to 1.55; P = .42). For BAT, 50% decline in PSA (PSA50) was 28.2% of patients versus 25.3% for enzalutamide. At crossover, PSA50 response occurred in 77.8% of patients crossing to enzalutamide and 23.4% to BAT. The PSA-PFS for enzalutamide increased from 3.8 months after abiraterone to 10.9 months after BAT. The PFS2 for BAT→enzalutamide was 28.2 versus 19.6 months for enzalutamide→BAT (HR, 0.44; 95% CI, 0.22 to 0.88; P = .02). OS was 32.9 months for BAT versus 29.0 months for enzalutamide (HR, 0.95; 95% CI, 0.66 to 1.39; P = .80). OS was 37.1 months for patients crossing from BAT to enzalutamide versus 30.2 months for the opposite sequence (HR, 0.68; 95% CI, 0.36 to 1.28; P = .225). BAT adverse events were primarily grade 1-2. Patient-reported QoL consistently favored BAT. CONCLUSION: This randomized trial establishes meaningful clinical activity and safety of BAT and supports additional study to determine its optimal clinical integration. BAT can sensitize CRPC to subsequent antiandrogen therapy. Further study is required to confirm whether sequential therapy with BAT and enzalutamide can improve survival in men with CRPC.
引用
- Denmeade SR, Wang H, Agarwal N, et al. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021. PMID: 33617303. doi:10.1200/JCO.20.02759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。